Pell Bio-Med Technology（6949）株式概要ペル・バイオメッド・テクノロジー社はバイオメディカル企業で、治療応用のための細胞培養技術や手法の開発に従事している。 詳細6949 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去5年間で収益は年間14.3%減少しました。 収益が 100 万ドル未満 ( NT$26M )すべてのリスクチェックを見る6949 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$669.0062.4k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-425m27m2016201920222025202620282031Revenue NT$25.8mEarnings NT$4.7mAdvancedSet Fair ValueView all narrativesPell Bio-Med Technology Co., Ltd. 競合他社Lin BioScienceSymbol: TPEX:6696Market cap: NT$32.8bSunmax BiotechnologySymbol: TPEX:4728Market cap: NT$20.9bEver Supreme Bio TechnologySymbol: TPEX:6712Market cap: NT$12.3bTaiMed BiologicsSymbol: TPEX:4147Market cap: NT$13.8b価格と性能株価の高値、安値、推移の概要Pell Bio-Med Technology過去の株価現在の株価NT$669.0052週高値NT$929.0052週安値NT$127.00ベータ1.51ヶ月の変化-22.21%3ヶ月変化n/a1年変化422.66%3年間の変化n/a5年間の変化n/aIPOからの変化549.51%最新ニュースReported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).お知らせ • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city TaiwanNew Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).最新情報をもっと見るRecent updatesReported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).お知らせ • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city TaiwanNew Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).お知らせ • May 06Pell Bio-Med Technology Co., Ltd. to Report Q1, 2025 Results on May 13, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025Reported Earnings • Mar 18Full year 2024 earnings released: NT$6.83 loss per share (vs NT$8.62 loss in FY 2023)Full year 2024 results: NT$6.83 loss per share (improved from NT$8.62 loss in FY 2023). Net loss: NT$389.4m (loss narrowed 2.3% from FY 2023).お知らせ • Mar 12Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,327, t`i ting ta tao, neihu district, taipei city Taiwanお知らせ • Mar 04Pell Bio-Med Technology Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.7% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$561k). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).分析記事 • Feb 05Pell Bio-Med Technology (TWSE:6949) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$1.76 loss per share (vs NT$2.64 loss in 3Q 2023)Third quarter 2024 results: NT$1.76 loss per share (improved from NT$2.64 loss in 3Q 2023). Net loss: NT$100.8m (loss narrowed 15% from 3Q 2023).お知らせ • Nov 01Pell Bio-Med Technology Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023)Second quarter 2024 results: NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023). Net loss: NT$101.5m (loss narrowed 17% from 2Q 2023).お知らせ • Aug 06Pell Bio-Med Technology Co., Ltd. to Report Q2, 2024 Results on Aug 13, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q2, 2024 results on Aug 13, 2024分析記事 • Jul 22Pell Bio-Med Technology (TWSE:6949) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • May 29New major risk - Revenue and earnings growthRevenue has declined by 3.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 3.2% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$556k).お知らせ • Mar 27PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024.株主還元6949TW BiotechsTW 市場7D-2.6%-1.3%2.6%1Y422.7%28.2%94.7%株主還元を見る業界別リターン: 6949過去 1 年間で28.2 % の収益を上げたTW Biotechs業界を上回りました。リターン対市場: 6949過去 1 年間で94.7 % の収益を上げたTW市場を上回りました。価格変動Is 6949's price volatile compared to industry and market?6949 volatility6949 Average Weekly Movement8.9%Biotechs Industry Average Movement6.0%Market Average Movement6.2%10% most volatile stocks in TW Market12.2%10% least volatile stocks in TW Market2.5%安定した株価: 6949 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6949の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2017n/aSteve Linwww.pellbmt.comペル・バイオメッド・テクノロジー株式会社はバイオメディカル企業で、治療応用のための細胞培養技術や手法の開発に従事している。同社の商業製品には、優良組織実践実験インフラ、再生医療用脂肪由来幹細胞（ADSC）、がんに対するCIKおよびDC-CIKなどがある。また、各種がんに対する医薬品、細胞免疫療法、幹細胞再生療法技術の開発も行っている。さらに、キメラ抗原受容体T細胞（CAR-T）、CAR-NKおよびCAR-?さらに、B-NHL、卵巣がん、多発性骨髄腫、甲状腺がんを適応症とする製品を開発している。同社は2017年に設立され、台湾の台北を拠点としている。もっと見るPell Bio-Med Technology Co., Ltd. 基礎のまとめPell Bio-Med Technology の収益と売上を時価総額と比較するとどうか。6949 基礎統計学時価総額NT$43.30b収益（TTM）-NT$424.75m売上高(TTM)NT$25.85m1,675xP/Sレシオ-101.9xPER（株価収益率6949 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6949 損益計算書（TTM）収益NT$25.85m売上原価NT$35.68m売上総利益-NT$9.83mその他の費用NT$414.93m収益-NT$424.75m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-6.56グロス・マージン-38.02%純利益率-1,643.28%有利子負債／自己資本比率3.4%6949 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:02終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pell Bio-Med Technology Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).
Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).
お知らせ • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city Taiwan
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).
Reported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).
Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).
お知らせ • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city Taiwan
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).
Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).
お知らせ • May 06Pell Bio-Med Technology Co., Ltd. to Report Q1, 2025 Results on May 13, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025
Reported Earnings • Mar 18Full year 2024 earnings released: NT$6.83 loss per share (vs NT$8.62 loss in FY 2023)Full year 2024 results: NT$6.83 loss per share (improved from NT$8.62 loss in FY 2023). Net loss: NT$389.4m (loss narrowed 2.3% from FY 2023).
お知らせ • Mar 12Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,327, t`i ting ta tao, neihu district, taipei city Taiwan
お知らせ • Mar 04Pell Bio-Med Technology Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.7% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$561k). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
分析記事 • Feb 05Pell Bio-Med Technology (TWSE:6949) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$1.76 loss per share (vs NT$2.64 loss in 3Q 2023)Third quarter 2024 results: NT$1.76 loss per share (improved from NT$2.64 loss in 3Q 2023). Net loss: NT$100.8m (loss narrowed 15% from 3Q 2023).
お知らせ • Nov 01Pell Bio-Med Technology Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024
Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023)Second quarter 2024 results: NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023). Net loss: NT$101.5m (loss narrowed 17% from 2Q 2023).
お知らせ • Aug 06Pell Bio-Med Technology Co., Ltd. to Report Q2, 2024 Results on Aug 13, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q2, 2024 results on Aug 13, 2024
分析記事 • Jul 22Pell Bio-Med Technology (TWSE:6949) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • May 29New major risk - Revenue and earnings growthRevenue has declined by 3.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 3.2% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$556k).
お知らせ • Mar 27PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024.
